Member Info for inanaco

CD25 depletion can unmask or enhance responses ? been mentioned before .. can't see that in the link

On That note all problems generating this vaccine have been solved .... as per RNS

The Company has completed the key process development work to allow for the Good Manufacturing Practice (GMP) manufacture of the three Modi-1 peptides each conjugated to the Amplivant adjuvant molecule. A defined manufacturing process is a key component for CMC (Chemistry, Manufacturing and Control) regulatory submissions required to support the filing of a clinical trial application (CTA) in the UK, toxicology studies and supply of the Modi-1 vaccine for tThe planned Phase 1/2 clinical study is anticipated to commence in H2 2019.

but the CFD follows the "sit and wait ones" ...

it takes its pricing and leverage structure off the main market ....

sorry i don't follow your post ...

it's a derivative its NOT a share

lets assume it is a share and you buy 500 million on your CFD contract

hang on that is more than the entire issued share base .....

researcher 1 ...... by the way you have not purchased the full contract as its a leveraged position which indicates you are gambling from a small capital base

best of luck with that one

CFD don't show up at all !! its a "" contract for difference """ not a contract to buy a share on your behalf

deals will follow ....

is the gold standard of Standard of Care which is why Val on the 201 trial is aiming at the results from Abiraterone

which is why MTFB trial against Vancomycin

Scancell don't have to have a deal ... all it has to do is prove itself better than current standard of care .....

what better way than to double the efficacy of the current standard of care .. SCIB1

Moditope is only competing with undertakers

Page 4

challenging questions .. how to reply .

Make it up so that you sound plausible ...

many trials at this late stage give a pretty good read out at 12 months

https://www.geekwire.com/2018/immunotherapy-dramatically-increases-survival-rate-lung-cancer-patients-according-new-study/

Space Cadets handbook

Page 3 ...

If you don't understand .. Stamp your feet and throw a tantrum .. its makes you appear intelligent to other Space cadets

it's the Bonding phase of the team build

Just to put the record straight you posted

""" I notice you are picking the bits out of the article I linked. Are any of your deductions mentioned in any of the Scancell releases or updates? """"

you have posted nothing !!!! ... other than the link .. !!!! and if you follow my history i have already pasted it before

and if you actually do study it, all that i have posted can be found in Scancells research papers if you know what to look for ...

have a good day

so to turn off the signal completely may have consequence

"""" this approach may require further optimization as premature IFN-? blocking might interfere to generate an effective anti-tumor response """"

well that's already proven ...

your problem is the entire immune system works by secreting Interferon Gamma ..

the cancer hijacks that and uses that signalling to hide itself ...

Immunobody .... SCIB1

once the HIGH avidity T cells have engaged and the PD-1 on those T cells are protected from the cancers ability to turn them off

then the Interferon gamma shifts from the Dark side to The Bright side it attracts more T cells and clonal expansion begins

the Balance shifts back from the Cancer to the immune system ....

...

Amongst more than 200 genes induced by IFN-? [82], many of those genes are the molecules involved in cancer cell immune evasion, such as PD-L1, PD-L2, CTLA-4, CIITA, non-classical MHC class Ib antigens, IDO1, CXCL12 etc. [18,19,83]. IFN-? promotes expression of PD-L1 and PD-L2 not only in tumor cells, but also in other stromal cells including immune infiltrating cells, and suppresses the effector function of tumor-specific T cells or NK cells through an interaction with an immune inhibitory receptor, PD-1 [84,85,86]. IFN-? induced PD-L1/2 expression has also been referred to as a mechanism of adaptive immune resistance to immune checkpoint therapy

well that is handled by Keytruda ... Proven at Phase 3 ...

PART one

IFN-? selects tumor cells capable of evading immune responses possibly through a constant selective immune pressure. Such immune-evaded tumor cells are frequently found to lose their tumor antigen expression, which can be a result of reduced expression levels of tumor antigens, loss of MHC class I expression, or impaired antigen processing machinery in tumor cells [67,68]. It was reported that IFN-? exposure led to downregulation of endogenous tumor antigen expression in M14 melanoma and CT26 colon cancer cell lines [69,70]. It is also reported that human melanoma cell lines treated with IFN-? for prolonged periods lost melan-A and gp100 processing and subsequently evaded CTL recognition [71]. In addition to classical MHC class I regulation, IFN-? induced expression of non-cognate MHC-I molecules on mouse melanoma cells, which in turn limited tumor-antigen specific T-cell activation and effector functions [72].

SCIB1 induces HIGH Avidity t cells to get over this problem of poor antigen expression

Moditope LOVES it ... all that stress and Inflammation on the cancer ... causing citrullination and in the presence of Interferon gamma ... Out Pops the epitope ........

To explain ....

The "" Bright side""" of Interferon Gamma

and The Dark side ...

and exactly how Scancell uses BOTH to its advantage ?

it's easy to simplify into two main groups that have the most negative effect

Do you want me to do that .. or would you prefer me to explain ?

mine do come with notes ........ that is just you trying to wriggle out ....

come on ... Ruck

you have pasted a research paper .........

you have not actually explained your post ... yet

waiting ...